Evidence map›Paper›PMID 37161257›Full record

ArticleTurkish journal of pharmaceutical sciences2023

Melis Erçelik, Berrin Tunca, Seçil Ak Aksoy, Çağla Tekin, Gülçin Tezcan

Open access · diamondAbstract read
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Life (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Melis ErçelikBursa Uludağ University, Faculty of Medicine, Department of Medical Biology, Bursa, Türkiye.ORCID 0000-0003-0366-2424
Berrin TuncaBursa Uludağ University, Faculty of Medicine, Department of Medical Biology, Bursa, Türkiye.ORCID 0000-0002-1619-6680
Seçil Ak AksoyBursa Uludağ University, İnegol Vocation School, Bursa, Türkiye.ORCID 0000-0002-3760-9755
Çağla TekinBursa Uludağ University, Faculty of Medicine, Department of Medical Biology, Bursa, Türkiye.ORCID 0000-0002-2568-3667
Gülçin TezcanBursa Uludağ University, Faculty of Dentistry, Department of Fundamental Sciences, Bursa, Türkiye.ORCID 0000-0002-5956-8755
Bursa Uludağ Üni̇versi̇tesi̇ · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The purpose of this study was to investigate the effect of Materials and Methods: A senescence β-galactosidase assay and a colony formation assay were used to determine the effects of OLE, TMZ, and OLE + TMZ on the cellular senescence and aggressiveness of GB cell lines T98G and U87MG. mRNA expression levels of p53, a senescence factor, interleukin (IL)-6, matrix metalloproteinases (MMP)-9, and nuclear factor kappa B1 (NF-κB1) as SASP factors and Bcl-2 and Bax as senolytic markers were assessed using quantitative reverse transcription-real-time polymerase chain reaction. Cells were double-stained with acridine orange and propidium iodide to observe the cell morphology. Results: TMZ increased the senescence rate of GB cells (p<0.001). Besides, OLE + TMZ reduced the proportion of senescent cells ( Conclusion: Collectively, our findings presented the inhibitory effect of OLE on TMZ-mediated SASP-factor production in GB and, accordingly, its potential contribution to elongate the time of recurrence.

Indexed as

GlioblastomaOlea europaea leaf extractSASPsenescencetemozolomide

Identifiers

PMID37161257
PMCPMC10176625
OpenAlexW4281685111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.